NDLI: Effect of tumour necrosis factor- inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.

Please wait, while we are loading the content...

Hypertension is associated with serologically active disease in patients with systemic lupus erythematosus: role of increased Th1/Th2 ratio and oxidative stress.

Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis.

Short-term treatment with a gonadotropin-releasing hormone antagonist, cetrorelix, in rheumatoid arthritis (AGRA): a randomized, double-blind, placebo-controlled study.

Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren's syndrome.

Effects of wearing high heels on the forefoot: an MRI evaluation.

HLA-DRB1 associations with rheumatoid arthritis-related pulmonary fibrosis.

Systemic myositis due to Campylobacter infection.

Immune-mediated necrotizing myopathies are serologically heterogeneous and autoantibodies may predict their clinical phenotype: two cases associated with anti-Pl7 antibodies.

Change in CXCL10 on treatment with methotrexate similar to that reported with infliximab: comments on the article by Eriksson et al.

Effect of tumour necrosis factor- inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.

Year: 2014

Year: 2013 Volume: 42

Year: 2012 Volume: 126

Year: 2012 Volume: 41

Year: 2011 Volume: 125

Year: 2011 Volume: 40

Year: 2010 Volume: 124

Year: 2010 Volume: 39

Year: 2009 Volume: 38

Year: 2008 Volume: 37

Year: 1998 Volume: 27

Year: 1987 Volume: 16

Year: 1980 Volume: 9

Effect of tumour necrosis factor- inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Korkosz, M. Gasowski, J. Leszczynski, P. Pawlak-Bus, K. Jeka, S. Siedlar, M. Grodzicki, T.
Description	Country affiliation: Poland Author Affiliation: Korkosz M ( Division of Rheumatology, Department of Internal Medicine and Gerontology, Jagiellonian University Medical College , Krakow , Poland.)
Abstract	OBJECTIVES: To examine changes in serum levels of the bone remodelling molecules dickkopf-1 (Dkk-1), sclerostin, wingless-type protein-3a (Wnt-3a), and bone morphogenetic protein-7 (BMP-7) during 6 months of anti-tumour necrosis factor (anti-TNF) treatment in ankylosing spondylitis (AS) patients with high disease activity. METHOD: We included 40 patients with axial AS: 20 patients with high disease activity were assigned to treatment with TNF inhibitor and 20 with low disease activity were assigned to non-steroidal anti-inflammatory drug (NSAID) treatment. Markers of bone remodelling and inflammation were assessed at baseline and after 6 months. RESULTS: In the TNF inhibitor-treated group Dkk-1 decreased significantly from 196.8 pg/mL [95% confidence interval (CI) 94.1-399.0] to 116.3 pg/mL (95% CI 38.0-301.6) and BMP-7 increased significantly from 1.4 pg/mL (95% CI 0-23.0) to 20.3 pg/mL (95% CI 4.9-41.3). There was a significant negative correlation between Dkk-1 and BMP-7 at 6 months (r = -0.64, p = 0.004) in this group. Non-parametric regression analysis adjusted for disease duration, age, sex, baseline modified Stoke's Ankylosing Spondylitis Spine Score (mSASSS), and baseline C-reactive protein (CRP) confirmed a statistically significant effect of treatment on time-related changes of Dkk-1 and BMP-7. Erythrocyte sedimentation rate (ESR), CRP, and also the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score decreased significantly in the anti-TNF-treated group. CONCLUSIONS: Among the potential biomarkers of bone remodelling in AS, Dkk-1 and BMP-7 displayed significant time alterations and correlative interactions during anti-TNF treatment.
File Format	HTM / HTML
ISSN	03009742
e-ISSN	15027732
Journal	Scandinavian Journal of Rheumatology
Issue Number	1
Volume Number	43
Language	English
Publisher	Taylor & Francis
Publisher Date	2014-01-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Rheumatology Antirheumatic Agents Pharmacology Bone Morphogenetic Protein 7 Blood Intercellular Signaling Peptides And Proteins Spondylitis, Ankylosing Tumor Necrosis Factor-alpha Antagonists & Inhibitors Therapeutic Use Bone Morphogenetic Proteins Genetic Markers Severity Of Illness Index Drug Therapy Wnt3a Protein
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology Rheumatology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.

Serum levels of inhibitors of wingless / beta-catenin in patients with ankylosing spondylitis and the relationship with anti-tumour necrosis factor alpha treatments

Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic review.

Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis.

Bone morphogenetic proteins and Dickkopf-1 in ankylosing spondylitis.

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

The impact of tumor necrosis factor inhibitors on radiographic progression in ankylosing spondylitis.

The role of bone morphogenetic proteins in ankylosing spondylitis

Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment.

Effect of tumour necrosis factor- inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.

Similar Documents

Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.

Serum levels of inhibitors of wingless / beta-catenin in patients with ankylosing spondylitis and the relationship with anti-tumour necrosis factor alpha treatments

Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic review.

Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis.

Bone morphogenetic proteins and Dickkopf-1 in ankylosing spondylitis.

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

The impact of tumor necrosis factor inhibitors on radiographic progression in ankylosing spondylitis.

The role of bone morphogenetic proteins in ankylosing spondylitis

Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment.

Effect of tumour necrosis factor- inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.